New drug duo aims to control Tough-to-Treat lung cancers
NCT ID NCT04701307
Summary
This study is testing whether combining two drugs, niraparib and dostarlimab, can help control recurrent small cell lung cancer and other aggressive neuroendocrine cancers. It is for adults whose cancer has returned after at least one prior treatment. The goal is to see if this combination can shrink tumors and keep the cancer from progressing for a meaningful period of time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIB LUNG CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.